The activity of letrozole in patients with advanced or recurrent endometrial cancer and correlation with biological markers - a study of the National Cancer Institute of Canada Clinical Trials Group
- 1 July 2004
- journal article
- clinical trial
- Published by Elsevier in International Journal of Gynecologic Cancer
- Vol. 14 (4) , 650-658
- https://doi.org/10.1111/j.1048-891x.2004.14419.x
Abstract
No abstract availableKeywords
This publication has 53 references indexed in Scilit:
- Prognostic significance of Bcl-2, p53 overexpression, and lymph node metastasis in surgically staged endometrial carcinomaAmerican Journal of Obstetrics and Gynecology, 2002
- Tamoxifen in the Treatment of Advanced or Recurrent Endometrial Carcinoma: A Gynecologic Oncology Group StudyJournal of Clinical Oncology, 2001
- p53 as a significant prognostic marker in endometrial carcinomaInternational Journal of Gynecologic Cancer, 2000
- Oral Medroxyprogesterone Acetate in the Treatment of Advanced or Recurrent Endometrial Carcinoma: A Dose-Response Study by the Gynecologic Oncology GroupJournal of Clinical Oncology, 1999
- Prognostic Significance of Angiogenesis and Ki-67, p53, and p21 Expression: A Population-Based Endometrial Carcinoma StudyJournal of Clinical Oncology, 1999
- Stage IV endometrial carcinoma: a 10 year review of patients.The British Journal of Radiology, 1999
- Lack of bcl-2 Persistence: An Independent Prognostic Indicator of Poor Prognosis in Endometrial CarcinomaGynecologic Oncology, 1998
- Bcl-2 expression and prognosis of patients with endometrial carcinomaInternational Journal of Cancer, 1998
- Oestrogen and Progestin Receptors as Prognostic Indicators in Endometrial Cancer: A review of the literatureActa Oncologica, 1989
- Endometrial carcinoma: Steroid receptors and response to medroxyprogesterone acetateGynecologic Oncology, 1985